Skip to main content
SynAct Pharma logo

SynAct Pharma — Investor Relations & Filings

Ticker · SYNACT ISIN · SE0008241491 LEI · 549300RRYIEFEQ72N546 ST Manufacturing
Open in API
Filings indexed 223 across all filing types
Latest filing 2022-12-22 AGM Information
Country SE Sweden
Listing ST SYNACT

About SynAct Pharma

https://synactpharma.com/en/

SynAct Pharma is a clinical-stage biotechnology company developing innovative medicines designed to resolve inflammation rather than solely inhibit it. The company's approach focuses on resolution therapy by leveraging melanocortin biology to restore immune balance. Its lead candidate, Resomelagon (AP1189), is a once-daily oral therapy that selectively activates melanocortin receptors on key immune cells. SynAct Pharma's development programs target a broad range of inflammatory conditions, including early intervention in chronic diseases to limit progression and the modulation of hyperinflammatory stages in acute viral diseases to reduce the risk of severe organ dysfunction.

Recent filings

Filing Released Lang Actions
Change in Nomination Committee prior to AGM 2023 in SynAct Pharma
AGM Information Classification · 95% confidence The document explicitly discusses a change in the composition of the Nomination Committee *prior to the Annual General Meeting (AGM) 2023*. It details which members are leaving and entering based on ownership changes. While it relates to the AGM, the core subject is the composition and function of the committee responsible for proposing board members and fees, which falls under governance and board structure information. However, since the document is an announcement regarding the composition of a committee related to the upcoming AGM, and it is not the AGM presentation itself (AGM-R) or a general governance report (CGR), the most fitting category is Board/Management Information (MANG) as it concerns the composition of a key governing body's nominating committee, or potentially Governance Information (CGR). Given the specific focus on the Nomination Committee composition change leading up to the AGM, and the fact that the AGM itself is mentioned as the context for the committee's work, MANG (Board/Management Information) is a strong fit for changes in key governance personnel structures. Alternatively, CGR (Governance Information) covers board structure. Since this is a specific, timely announcement about a committee composition change, MANG is slightly more precise than the broader CGR.
2022-12-22 English
Kallelse till extra bolagsstämma i SynAct Pharma AB
AGM Information Classification · 99% confidence The document is titled "Kallelse till extra bolagsstämma i SynAct Pharma AB" (Notice of Extraordinary General Meeting in SynAct Pharma AB). It details the date, time, location, requirements for participation (shareholder registration, notification deadlines), agenda items, and proposed resolutions for the meeting. Key agenda items involve approving a related-party transaction (acquisition of TXP Pharma AG) and a corresponding share issue (apportemission), as well as establishing a new employee option program. This content is characteristic of a formal notice calling shareholders to a meeting to vote on significant corporate actions, which aligns perfectly with the definition of an Annual General Meeting (AGM) or Extraordinary General Meeting (EGM) related material. Since the document is the official notice calling the meeting and detailing the proposals, the most appropriate classification is AGM-R (AGM Information), as it serves as the primary material for the upcoming meeting.
2022-12-12 Swedish
Notice of extraordinary general meeting in SynAct Pharma AB
AGM Information Classification · 98% confidence The document is explicitly titled "Notice of extraordinary general meeting in SynAct Pharma AB" and details the date, time, location, and procedures for shareholders to attend and vote. The proposed agenda items include resolutions regarding the acquisition of another company (TXP Pharma AG) and the issuance of new shares/warrants, which are typical items requiring shareholder approval at a general meeting. This content strongly aligns with the purpose of a notice for a general meeting, which is often accompanied by proxy materials or voting information. Since the document is a formal notice inviting shareholders to vote on specific corporate actions, it is best classified as related to the Annual General Meeting (AGM-R), even though it is an 'extraordinary' meeting, as AGM-R covers materials shared during general meetings.
2022-12-12 English
SynAct Pharma carries out a directed share issue of SEK 80 million in connection with the acquisition of TXP Pharma
Share Issue/Capital Change Classification · 100% confidence The document is a press release announcing a 'directed share issue' of SEK 80 million by SynAct Pharma. It details the number of shares issued, the subscription price, the rationale for the capital raise, and the impact on the company's share capital and dilution. This falls squarely under the definition of a 'Share Issue/Capital Change' (SHA) as it describes a specific corporate action involving the issuance of new shares to raise capital.
2022-12-12 English
SynAct Pharma genomför en riktad nyemission om 80 miljoner kronor med anledning av förvärvet av TXP Pharma
Share Issue/Capital Change Classification · 100% confidence The document is a press release from SynAct Pharma announcing a 'directed share issue' (riktad nyemission) to raise 80 million SEK. It details the number of shares, the subscription price, the purpose of the capital (financing development and operations), and the impact on the company's capital structure. This falls squarely under the definition of a 'Share Issue/Capital Change' (SHA) announcement, as it describes the issuance of new shares and the resulting changes to the company's share capital and voting rights.
2022-12-12 Swedish
SynAct Pharma to make strategic acquisition of Swiss biotech company TXP Pharma
M&A Activity Classification · 99% confidence The document details a strategic acquisition by SynAct Pharma of TXP Pharma, including transaction terms, funding via share issuance, related party disclosures, and scheduling of an Extraordinary General Meeting (EGM) for approval. This content relates to significant corporate financing and capital structure changes (share issuance for acquisition and a directed cash new issue). While it involves corporate actions, the core subject is the financing and capital structure change related to the M&A. However, the document also explicitly mentions an upcoming EGM for approval and provides details about the transaction, which is a major corporate event. Since the primary focus is the acquisition and the associated capital raise (share issuance), it strongly aligns with 'Capital/Financing Update' (CAP). It is not a standard 10-K, AR, or ER. It is too detailed for a simple RPA or RNS, as it contains the full substance of the transaction, not just an announcement that a report is attached. The mention of share issuance for consideration points directly to CAP.
2022-12-12 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.